Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Tuoyi

(Toripalimab)

Phase 3Monoclonal antibody

CCoherus Oncology, Inc.

Toripalimab is a cancer immunotherapy drug that helps the body's immune system fight certain types of cancer by blocking a protein that cancer cells use to hide from the immune system.[1] Tuoyi is currently being investigated across 81 indications[3], with its most advanced program in Phase 3.[1]

Tuoyi is one of 1204 small molecule programs targeting Cervical Cancer. It is currently in Phase 3.

81

Indications

323

Total Trials

110

Active Trials

1,203

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical CancerRecruiting

Non-Small Cell Lung CancerActive, not recruiting

Advanced Solid TumorsUnknown status

ChemotherapyNot yet recruiting

Advanced Malignant TumorsCompleted

Advanced Solid TumoursNot yet recruiting

Localized Colon CarcinomaRecruiting

Niemann-Pick Disease Type BUnknown

Esophageal Squamous Cell CarcinomaRecruiting

Nasopharyngeal CarcinomaRecruiting

Cervical CancerPhase 2

Recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Advanced Solid TumorsPhase 2

Unknown status

ChemotherapyPhase 3

Not yet recruiting

Advanced Malignant TumorsPhase 2

Completed

Advanced Solid TumoursPhase 2

Not yet recruiting

Localized Colon CarcinomaPhase 2

Recruiting

Niemann-Pick Disease Type BPreclinical

Unknown

Esophageal Squamous Cell CarcinomaPhase 3

Recruiting

Nasopharyngeal CarcinomaPhase 3

Recruiting

Showing 10 of 81 indications

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tuoyi

CCoherus Oncology, Inc.

Voltaren

Methylthioninium Chloride

PProvepharm SAS

Tricor

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Chantix

PPrism Pharmaceuticals

Recombinant Human Endostatin

PPeking University Third Hospital

Tianeptine

Ablavar

LLantheus Medical Imaging

Naltrexone/bupropion

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Cervical Cancer

NCT06416696

Phase 2Recruiting

Breast Cancer

NCT06178159

Phase 2Recruiting

Cervical Adenocarcinoma

NCT06124963

Phase 2Recruiting

Renal Insufficiency

NCT06354231

Phase 1/2Not yet recruiting

Melanoma

NCT05539118

Phase 2Active, not recruiting

Nasopharyngeal Carcinoma

NCT04517214

Clinical

Trials by Indication[1]

Nasopharyngeal Carcinoma15 trials

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Active, not recruiting·FFudan University·Phase 2·NCT04517214·100 enrolled

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Recruiting·SSun Yat-sen University·Phase 3·NCT04778956·218 enrolled

Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma

Unknown status·FFirst People's Hospital of Foshan·Phase 2·NCT04446663·50 enrolled

Show 12 more trials

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Recruiting·SSun Yat-sen University·Phase 2·NCT06323239·148 enrolled

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

Recruiting·MMan Hu·Phase 3·NCT07340515·300 enrolled

GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.

Recruiting·SSun Yat-sen University·Phase 2·NCT06851247·47 enrolled

Adaptive Immunotherapy for Nasopharyngeal Carcinoma

Recruiting·SSun Yat-sen University·Phase 3·NCT07154069·802 enrolled

PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

Unknown status·XXIANG YANQUN·Phase 2·NCT05229315·45 enrolled

Timing Optimization of Immunotherapy During Neoadjuvant Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT07388836·198 enrolled

Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Recruiting·XXinqiao Hospital of Chongqing·Phase 2·NCT05147844·40 enrolled

TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

Recruiting·SSun Yat-sen University·Phase 2·NCT06912711·70 enrolled

Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

Recruiting·—·Phase 3·NCT04376866·204 enrolled

TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT06987123·62 enrolled

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

Recruiting·MMediLink Therapeutics (Suzhou) Co., Ltd.·Phase 1/2·NCT07258979·202 enrolled

Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.

Not yet recruiting·SSun Yat-sen University·Phase 1/2·NCT07320963·52 enrolled

Toripalimab13 trials

Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)

Completed·SSun Yat-sen University·Phase 2·NCT06618014·51 enrolled

HAIC Plus Lenvatinib and Toripalimab for Advanced HCC

Completed·SShi Ming·Phase 2·NCT04044313·36 enrolled

Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT06020755·17 enrolled

Show 10 more trials

Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6

Recruiting·PPeking Union Medical College Hospital·N/A·NCT06028672·40 enrolled

A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers

Completed·EEucure (Beijing) Biopharma Co., Ltd·Phase 2·NCT05031494·40 enrolled

Phase II of Lenvatinib Plus Toripalimab for Advanced HCC

Withdrawn·SSun Yat-sen University·Phase 2·NCT03919383

Toripalimab Combined With Definitive CCRT for LACC Patients

Recruiting·RRuijin Hospital·N/A·NCT06256224·150 enrolled

NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC

Not yet recruiting·PPeking University Third Hospital·Phase 2·NCT07412171·40 enrolled

Toripalimab Combined With SBRT for NSCLC

Active, not recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT06293690·40 enrolled

Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell

Not yet recruiting·TTaizhou Hospital·Phase 3·NCT06441344·136 enrolled

Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

Unknown status·PPeking University·Phase 2·NCT04880811·43 enrolled

Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06221670·51 enrolled

HAIC Combined With Toripalimab and Donafenib for Advanced BTC

Unknown status·LLu Wang, MD, PhD·Phase 2·NCT05350943·70 enrolled

Esophageal Squamous Cell Carcinoma8 trials

Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma

Completed·SShanghai Junshi Bioscience Co., Ltd.·Phase 3·NCT03829969·514 enrolled

Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma

Unknown status·HHenan Cancer Hospital·Phase 2·NCT04229849·164 enrolled

Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Unknown status·WWei Ren·Phase 2·NCT04644250·32 enrolled

Show 5 more trials

Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma

Terminated·PPeking University·Phase 2·NCT04804696·10 enrolled

A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07272291·48 enrolled

BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Not yet recruiting·HHenan Provincial People's Hospital·Phase 2·NCT06588335·20 enrolled

Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Unknown status·SSun Yat-sen University·Phase 2·NCT04844385·124 enrolled

Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Unknown status·SSichuan Cancer Hospital and Research Institute·Phase 2·NCT04177797·20 enrolled

Esophageal Cancer7 trials

Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer

Unknown status·RRenJi Hospital·Phase 2·NCT04437212·20 enrolled

Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)

Recruiting·SSun Yat-sen University·Phase 2·NCT06187597·140 enrolled

Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer

Unknown status·JJianhua Fu·Phase 2·NCT04006041·44 enrolled

Show 4 more trials

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

Recruiting·BBeijing Konruns Pharmaceutical Co., Ltd.·Phase 2·NCT07481058·60 enrolled

Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer

Completed·MMian XI·Phase 2·NCT04005170·42 enrolled

Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy

Unknown status·TTaizhou Hospital·Phase 2/3·NCT05817201·60 enrolled

Toripalimab Combined With Radiotherapy and S-1 for Older Patients With Esophageal Cancer

Recruiting·HHebei Medical University Fourth Hospital··NCT06009705·56 enrolled

Chemotherapy7 trials

Toripalimab Plus TPF Chemotherapy and Radiotherapy for LA-HPSCC

Unknown status·SSun Yan·Phase 2·NCT04624308·81 enrolled

Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC

Unknown status·ZZhejiang University·Phase 2·NCT04653480·61 enrolled

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

Unknown status·TTaizhou Hospital·Phase 2·NCT04363255·20 enrolled

Show 4 more trials

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 3·NCT05342194·480 enrolled

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 3·NCT04772287·341 enrolled

LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07325539·55 enrolled

Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

Not yet recruiting·SSichuan University·Phase 1·NCT06732258·12 enrolled

80 more indications

Breast Cancer6 trials

Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 4·NCT05291910·70 enrolled

Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients

Active, not recruiting·FFudan University·Phase 2·NCT04418154·70 enrolled

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Recruiting·RRemeGen Co., Ltd.·Phase 2·NCT06389006·79 enrolled

Show 3 more trials

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

Recruiting·RRemeGen Co., Ltd.·Phase 2·NCT06642545·40 enrolled

Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer

Not yet recruiting·HHenan Cancer Hospital·Phase 2·NCT07256964·216 enrolled

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Recruiting·RRemeGen Co., Ltd.·Phase 2·NCT06178159·40 enrolled

Melanoma5 trials

KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma

Unknown status·SShanghai Kanda Biotechnology Co., Ltd.·Phase 1/2·NCT05723432·84 enrolled

Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma

Not yet recruiting·XXijing Hospital·Phase 1/2·NCT05539118·48 enrolled

A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma

Unknown status·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT04884997·90 enrolled

Show 2 more trials

Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma

Unknown status·FFudan University·Phase 2·NCT04248387·100 enrolled

A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma

Completed·NNanjing Leads Biolabs Co.,Ltd·Phase 1·NCT04640545·79 enrolled

Patients With Advanced Solid Tumors5 trials

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Active, not recruiting·FFBD Biologics Limited·Phase 1/2·NCT06771622·500 enrolled

Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

Completed·HHutchison Medipharma Limited·Phase 2·NCT04169672·248 enrolled

A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors

Withdrawn·ZZhejiang Genfleet Therapeutics Co., Ltd.·Phase 1/2·NCT05165849

Show 2 more trials

A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Completed·GGenfleet Therapeutics (Shanghai) Inc.·Phase 1/2·NCT04914286·148 enrolled

Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1/2·NCT07245901·60 enrolled

Gastric Cancer5 trials

Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer

Unknown status·AAiping Zhou·Phase 2·NCT04119622·30 enrolled

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

Active, not recruiting·RRemeGen Co., Ltd.·Phase 2/3·NCT05980481·201 enrolled

A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer

Not yet recruiting·—·Phase 2·NCT06283121·30 enrolled

Show 2 more trials

Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer

Unknown status·SShanghai East Hospital·Phase 1·NCT06078982·39 enrolled

Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer

Unknown status·TTao Zhang·Phase 2·NCT04563975·54 enrolled

Small Cell Lung Cancer5 trials

The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer

Unknown status·WWuhan University·Phase 2·NCT05162196·57 enrolled

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

Recruiting·SShanghai Chest Hospital·Phase 2·NCT05798845·124 enrolled

Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer

Not yet recruiting·FFudan University··NCT07308379·1,200 enrolled

Show 2 more trials

Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT07097948·40 enrolled

Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer

Unknown status·TThird Military Medical University·N/A·NCT04731909·80 enrolled

Advanced Solid Tumors5 trials

Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors

Unknown status·SSun Yat-sen University·Phase 2·NCT03810339·35 enrolled

HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors

Unknown status·HHutchison Medipharma Limited·Phase 1/2·NCT05173142·141 enrolled

A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors

Completed·EEucure (Beijing) Biopharma Co., Ltd·Phase 1/2·NCT04481009·26 enrolled

Show 2 more trials

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

Unknown status·SSichuan University·Phase 1/2·NCT04337463·60 enrolled

A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.

Recruiting·AAdvenchen Laboratories, LLC·Phase 1/2·NCT07392736·228 enrolled

Non-Small Cell Lung Cancer5 trials

Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer

Recruiting·NNorthern Jiangsu People's Hospital·Phase 2·NCT06065813·20 enrolled

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

Active, not recruiting·TTJ Biopharma Co., Ltd.·Phase 2/3·NCT06984588·450 enrolled

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT05891080·124 enrolled

Show 2 more trials

Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression

Recruiting·RRuijin Hospital·Phase 2·NCT06269211·29 enrolled

Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy

Recruiting·WWen-zhao ZHONG·Phase 2·NCT07039656·211 enrolled

Hepatocellular Carcinoma5 trials

Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.

Unknown status·HHenan Cancer Hospital·N/A·NCT05162898·90 enrolled

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Completed·SSun Yat-sen University··NCT04627012·600 enrolled

Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma

Unknown status·SShanghai Zhongshan Hospital·Phase 1/2·NCT04926532·30 enrolled

Show 2 more trials

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Recruiting·SSun Yat-sen University··NCT06333561·300 enrolled

Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

Recruiting·SSun Yat-sen University··NCT06323382·240 enrolled

Colorectal Cancer4 trials

A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

Not yet recruiting·—·Phase 1·NCT06283134·60 enrolled

Phase II Study of Toripalimab Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasis

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT03927898·40 enrolled

Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer

Unknown status·PPeking University·Phase 1/2·NCT04988191·44 enrolled

Show 1 more trial

Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer

Unknown status·PPeking Union Medical College Hospital··NCT04771715·100 enrolled

Immunotherapy4 trials

Immunotherapy After Radiotherapy in Elderly ESCC

Not yet recruiting·TThe Central Hospital of Lishui City·Phase 2·NCT05791136·30 enrolled

Thermal Ablation Followed by Immunotherapy for HCC

Unknown status·XXiangya Hospital of Central South University·Phase 1/2·NCT03864211·145 enrolled

The Optimal Radioimmunotherapy Combinations for Advanced TNBC

Recruiting·SSun Yat-sen University·Phase 2·NCT06735131·60 enrolled

Show 1 more trial

FMD and Neoadjuvant Chemo-immunotherapy in TNBC

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07378306·80 enrolled

PD-1antibody3 trials

PD-1 Antibody for Reactive EBV After BMT

Unknown status·—·Phase 1·NCT04690036·20 enrolled

High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery(RePASS)

Unknown status·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT04126460·41 enrolled

PD-1 Antibody Improve Mixed Chimerism

Unknown status·—·N/A·NCT04944511·20 enrolled

Pancreatic Cancer3 trials

Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer

Unknown status·SShouyao Holdings (Beijing) Co. LTD·Phase 1/2·NCT05580445·114 enrolled

AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer

Not yet recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT06080854·108 enrolled

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07469956·30 enrolled

Lymphoma3 trials

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma

Completed·SShanghai Junshi Bioscience Co., Ltd.·Phase 1·NCT03316144·13 enrolled

A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)

Recruiting·SSun Yat-sen University·Phase 3·NCT04365036·207 enrolled

Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma

Active, not recruiting·—·Phase 2·NCT06492629·43 enrolled

Biliary Tract Cancer3 trials

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

Not yet recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07159217·65 enrolled

Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer

Active, not recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06717464·110 enrolled

Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT06362317·300 enrolled

Nab-paclitaxel3 trials

Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma

Unknown status·—·N/A·NCT04443036·44 enrolled

Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

Unknown status·SSichuan Cancer Hospital and Research Institute·Phase 2·NCT04725448·27 enrolled

Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT04807140·57 enrolled

Lung Cancer3 trials

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

Not yet recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 2·NCT07309276·864 enrolled

A Real-World Study of Toripalimab in Chinese Patients With Lung Cancer(THUNDER Study)

Unknown status·QQianfoshan Hospital··NCT05652712·200 enrolled

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Completed·SShanghai Junshi Bioscience Co., Ltd.·Phase 1/2·NCT05664971·119 enrolled

Head and Neck Squamous Cell Carcinoma3 trials

Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

Not yet recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 3·NCT06647563·355 enrolled

Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma

Unknown status·TTianjin Medical University General Hospital·Phase 2·NCT05861557·23 enrolled

A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06208826·268 enrolled

Cervical Cancer3 trials

Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 1/2·NCT06093438·20 enrolled

Toripalimab for High-risk Locally Advanced Cervical Cancer

Active, not recruiting·—·Phase 2·NCT06416696·57 enrolled

Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT04973904·35 enrolled

Metastatic Urothelial Cancer2 trials

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

Recruiting·MMabwell (Shanghai) Bioscience Co., Ltd.·Phase 1/2·NCT06079112·100 enrolled

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

Recruiting·MMabwell (Shanghai) Bioscience Co., Ltd.·Phase 3·NCT06592326·460 enrolled

Urothelial Carcinoma2 trials

Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma

Unknown status·—·Phase 2·NCT04099589·64 enrolled

Probiotics in Advanced Urothelial Carcinoma

Recruiting·SSun Yat-sen University·Phase 2·NCT06904573·222 enrolled

Locally Advanced2 trials

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

Recruiting·TTang-Du Hospital·Phase 2·NCT07353723·10 enrolled

Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Recruiting·FFudan University·Phase 2·NCT05628922·198 enrolled

Metastatic Colorectal Cancer2 trials

Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer

Recruiting·FFudan University·Phase 2·NCT05963490·108 enrolled

Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal Cancer

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT04819516·10 enrolled

First-line Treatment2 trials

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07244874·41 enrolled

Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer

Recruiting·NNanfang Hospital, Southern Medical University·N/A·NCT05877573·53 enrolled

Oral Squamous Cell Carcinoma2 trials

Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients

Completed·SShanghai Jiao Tong University School of Medicine·Phase 1·NCT04473716·20 enrolled

Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT05803915·57 enrolled

Adenocarcinoma2 trials

Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Not yet recruiting·YYu jiren·Phase 2·NCT05970627·30 enrolled

Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Recruiting·YYu jiren·Phase 2·NCT05729646·90 enrolled

Renal Cell Carcinoma2 trials

Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

Completed·RRenJi Hospital·Phase 2·NCT04118855·20 enrolled

Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors

Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT05768464·30 enrolled

Advanced Solid Tumours2 trials

A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Recruiting·LLaNova Medicines Limited·Phase 1/2·NCT06868199·87 enrolled

A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Not yet recruiting·LLaNova Medicines Limited·Phase 2·NCT06873854·84 enrolled

Chemoradiotherapy2 trials

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Recruiting·SSun Yat-sen University·Phase 3·NCT05340491·212 enrolled

Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC

Not yet recruiting·SSun Yat-sen University·Phase 3·NCT07177794·242 enrolled

Advanced Malignancies2 trials

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Recruiting·TTopAlliance Biosciences·Phase 1·NCT04137900·499 enrolled

A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies

Withdrawn·SShanghai Junshi Bioscience Co., Ltd.·Phase 1·NCT05253105

Neoadjuvant Therapy2 trials

Neoadjuvant Therapy of SBRT Sequencial with Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)

Recruiting·SShanghai Chest Hospital·Phase 3·NCT06437977·478 enrolled

Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial

Not yet recruiting·SSun Yat-sen University·Phase 3·NCT07371897·154 enrolled

Anti-PD-1 Antibody2 trials

Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients

Unknown status·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT04164238·90 enrolled

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

Unknown status·—·Phase 2·NCT05461235·1 enrolled

Cholangiocarcinoma2 trials

Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma

Unknown status·UUnknown Sponsor·Phase 2·NCT03982680·30 enrolled

GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma

Recruiting·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT05215665·146 enrolled

Advanced NSCLC2 trials

Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC

Recruiting·SShanghai Chest Hospital·Phase 2·NCT06127303·54 enrolled

Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC

Completed·XXinqiao Hospital of Chongqing·Phase 2·NCT04238169·60 enrolled

Refractory Metastatic1 trial

Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC

Recruiting·DDan Feng·Phase 1/2·NCT07281716·24 enrolled

Induction Chemotherapy1 trial

Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC

Active, not recruiting·—·Phase 2·NCT05888402·50 enrolled

Prospective1 trial

HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial

Unknown status·SSun Yat-sen University·Phase 2·NCT04135690·60 enrolled

Adjuvant Therapy1 trial

A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer

Active, not recruiting·TTianjin Medical University Second Hospital·Phase 2·NCT06584435·100 enrolled

Malignancies1 trial

Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies

Recruiting·SSichuan University·Phase 1·NCT07004244·20 enrolled

PD-L1 Positive1 trial

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT07040644·150 enrolled

Hepatocellular1 trial

HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama

Unknown status·SSun Yat-sen University·Phase 2·NCT04627363·30 enrolled

Hypopharyngeal Carcinoma1 trial

Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma

Unknown status·FFudan University·Phase 2·NCT05420597·61 enrolled

Hepatocarcinoma1 trial

Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma

Unknown status·XXiangya Hospital of Central South University·Phase 2·NCT05240404·116 enrolled

Mucosal Melanoma1 trial

Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

Unknown status·FFudan University·Phase 2·NCT04472806·31 enrolled

Renal insufficiency1 trial

DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC

Recruiting·FFudan University·Phase 2·NCT06354231·20 enrolled

Thyroid Cancer1 trial

Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study

Unknown status·FFudan University·Phase 2·NCT04524884·10 enrolled

Cervical Adenocarcinoma1 trial

A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations

Recruiting·SShanghai Jiatan Pharmatech Co., Ltd·Phase 2·NCT06124963·20 enrolled

Rectal Adenocarcinoma1 trial

A Phase III Trial of Anus-preservation in Low Rectal Adenocarcinoma Based on MMR/MSI Status

Unknown status·ZZhejiang Cancer Hospital·Phase 3·NCT05669092·174 enrolled

Tracheal Squamous Cell Carcinoma1 trial

Toripalimab Combined With Chemotherapy in Primary Tracheal Squamous Cell Carcinoma

Unknown status·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT04716751·15 enrolled

Locally-advanced Rectal Cancer1 trial

Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT

Unknown status·WWest China Hospital·Phase 2·NCT05763927·44 enrolled

Conversion Therapy1 trial

Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC

Unknown status·SShanghai Zhongshan Hospital·Phase 3·NCT05056337·220 enrolled

Advanced Solid Malignancies1 trial

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Recruiting·IInnolake Biopharm·Phase 1/2·NCT05955105·200 enrolled

Efficacy and Safety1 trial

A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.

Recruiting·FFirst Affiliated Hospital of Zhejiang University·N/A·NCT06371274·29 enrolled

Locally Advanced Colon Cancer1 trial

Triplezumab Combined With CAPEOX Regimen in Neoadjuvant Therapy for Locally Advanced Colon Cancer

Unknown status·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT04389151·30 enrolled

NSCLC1 trial

The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001

Completed·SShanghai Junshi Bioscience Co., Ltd.·Phase 1·NCT03301688·38 enrolled

Neoadjuvant Immunotherapy1 trial

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT05800340·30 enrolled

Papilloma1 trial

Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer

Recruiting·UUniversity of Chicago·Phase 2·NCT07290621·30 enrolled

Advanced Malignant Solid Tumors1 trial

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Not yet recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 2·NCT07480733·480 enrolled

Triple-Negative Breast Cancer1 trial

To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT05491694·20 enrolled

Esophageal Carcinoma1 trial

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

Not yet recruiting·NNanfang Hospital, Southern Medical University·Phase 2·NCT05996484·25 enrolled

Advanced or Metastatic Solid Tumors1 trial

A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors

Not yet recruiting·CCoherus Oncology, Inc.·Phase 1·NCT06389526·48 enrolled

Solid Tumors1 trial

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

Terminated· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 1/2·NCT04284488·40 enrolled

Concurrent Chemoradiotherapy1 trial

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

Completed·GGenfleet Therapeutics (Shanghai) Inc.·Phase 2·NCT05386888·65 enrolled

Stereotactic Body Radiotherapy1 trial

Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTT

Unknown status·SSun Yat-sen University·Phase 2·NCT04169399·30 enrolled

Small Cell Carcinoma1 trial

Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy

Unknown status·SSun Yat-sen University·Phase 2·NCT03811379·43 enrolled

Advanced Malignant Tumors1 trial

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

Recruiting·LLaNova Medicines Limited·Phase 1/2·NCT05615974·139 enrolled

Metastasis1 trial

Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis

Unknown status·SSun Yat-sen University·Phase 2·NCT04170179·25 enrolled

Bladder Cancer1 trial

Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer

Completed·HHenan Cancer Hospital·Phase 2·NCT04553939·50 enrolled

Undifferentiated Pleomorphic Sarcoma1 trial

Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma

Unknown status·DDi Wu·Phase 2·NCT03946943·25 enrolled

Patients With Solid Tumors1 trial

Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials

Recruiting·—·Phase 1/2·NCT06612632·100 enrolled

Resectable NSCLC1 trial

Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC

Completed·YYongchang Zhang·Phase 2·NCT04144608·40 enrolled

Liposarcoma1 trial

APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

Recruiting· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 1/2·NCT04785196·95 enrolled

Targeted Therapy1 trial

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Not yet recruiting·Cchenxu·Phase 2·NCT07474064·146 enrolled

Neoadjuvant Chemotherapy1 trial

Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT07209189·75 enrolled

Unresectable1 trial

HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05493332·93 enrolled

Advanced1 trial

Study of LM-061 in Subjects in Advanced Tumors

Terminated·LLaNova Medicines Limited·Phase 1·NCT04737122·18 enrolled

Advanced Solid Tumor1 trial

A Phase I/II Study of TJ004309 for Advanced Solid Tumor

Active, not recruiting·TTJ Biopharma Co., Ltd.·Phase 1/2·NCT04322006·376 enrolled

Neuroendocrine Carcinoma1 trial

Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma

Unknown status·PPeking University·Phase 2/3·NCT03992911·336 enrolled

Locally Advanced Unresectable or Metastatic Solid Tumors1 trial

A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors

Recruiting·RRemeGen Co., Ltd.·Phase 1/2·NCT06038396·48 enrolled

Neoadjuvant Chemoimmunotherapy1 trial

Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer

Recruiting·FFudan University·Phase 2·NCT06039631·82 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Not yet recruiting·CChipscreen Biosciences, Ltd.·Phase 3·NCT07445295·558 enrolled

Sources

References

[1]
ClinicalTrials.gov — 323 trial records for Toripalimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Toripalimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Toripalimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Coherus Oncology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Programmed Cell Death Protein 1 Antagonist[2]
Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: CCoherus Oncology, Inc.

Related News